Xin Chen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6983126/publications.pdf

Version: 2024-02-01

115	8,121	38720 50	51562 86
papers	citations	h-index	g-index
120	120	120	10516
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gene Expression Patterns in Human Liver Cancers. Molecular Biology of the Cell, 2002, 13, 1929-1939.	0.9	779
2	The Metabolic Profile of Tumors Depends on Both the Responsible Genetic Lesion and Tissue Type. Cell Metabolism, 2012, 15, 157-170.	7.2	553
3	Increased Lipogenesis, Induced by AKT-mTORC1-RPS6 Signaling, Promotes Development of Human Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 1071-1083.e5.	0.6	453
4	Cholangiocarcinomas can originate from hepatocytes in mice. Journal of Clinical Investigation, 2012, 122, 2911-2915.	3.9	385
5	Yes-Associated Protein Up-regulates Jagged-1 and Activates the NOTCH Pathway in Human Hepatocellular Carcinoma. Gastroenterology, 2013, 144, 1530-1542.e12.	0.6	278
6	Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research. American Journal of Pathology, 2014, 184, 912-923.	1.9	271
7	Activation of Î²-Catenin and Yap1 in Human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice. Gastroenterology, 2014, 147, 690-701.	0.6	249
8	Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14771-14776.	3.3	193
9	AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene) Tj ETQq1 1 0.784314 rgBT /Ov 55, 833-845.	3.6	183
10	Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell, 2021, 39, 866-882.e11.	7.7	159
11	Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis, 2005, 26, 2050-2057.	1.3	123
12	An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene, 2005, 24, 3737-3747.	2.6	122
13	Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut, 2020, 69, 177-186.	6.1	121
14	A functional mammalian target of rapamycin complex 1 signaling is indispensable for câ€Mycâ€driven hepatocarcinogenesis. Hepatology, 2017, 66, 167-181.	3.6	119
15	A targetable LIFRâˆ'NF-ÎºBâˆ'LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nature Communications, 2021, 12, 7333.	5.8	117
16	ILâ€33 facilitates oncogeneâ€induced cholangiocarcinoma in mice by an interleukinâ€6â€sensitive mechanism. Hepatology, 2015, 61, 1627-1642.	3.6	115
17	Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. Journal of Hepatology, 2016, 64, 333-341.	1.8	115
18	Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. Scientific Reports, 2016, 6, 20484.	1.6	100

#	ARTICLE	IF	CITATIONS
19	Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology, 2008, 47, 1200-1210.	3.6	94
20	Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and pointâ€mutant Î²â€catenin. Hepatology, 2016, 64, 1587-1605.	3.6	92
21	Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by Î²-Catenin Mutations. Cell Metabolism, 2019, 29, 1135-1150.e6.	7.2	92
22	Harnessing big â€˜omicsâ€™ data and AI for drug discovery in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 238-251.	8.2	90
23	Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology, 2012, 56, 1331-1341.	3.6	87
24	Identifying strategies to target the metabolic flexibility of tumours. Nature Metabolism, 2020, 2, 335-350.	5.1	86
25	Differential effects of targeting Notch receptors in a mouse model of liver cancer. Hepatology, 2015, 61, 942-952.	3.6	85
26	Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancer. Cell Cycle, 2013, 12, 1999-2010.	1.3	82
27	Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology, 2016, 63, 1900-1913.	3.6	82
28	Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clinical Cancer Research, 2005, 11, 551-6.	3.2	82
29	Î²-Catenin signaling in hepatocellular carcinoma. Journal of Clinical Investigation, 2022, 132, .	3.9	80
30	Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene, 2018, 37, 3229-3242.	2.6	79
31	Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies. Hepatology, 2021, 73, 49-61.	3.6	79
32	Novel endothelial cell markers in hepatocellular carcinoma. Modern Pathology, 2004, 17, 1198-1210.	2.9	78
33	Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Research, 2002, 62, 4711-21.	0.4	78
34	Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. Journal of Hepatology, 2017, 67, 1194-1203.	1.8	77
35	Role of Cyclin D1 as a Mediator of c-Metâ€“ and Î²-Cateninâ€“Induced Hepatocarcinogenesis. Cancer Research, 2009, 69, 253-261.	0.4	74
36	EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology, 2014, 59, 1886-1899.	3.6	74

#	ARTICLE	IF	CITATIONS
37	Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities. Cancer Research, 2017, 77, 4355-4364.	0.4	74
38	The mTORC2â€Akt1 Cascade Is Crucial for câ€Myc to Promote Hepatocarcinogenesis in Mice and Humans. Hepatology, 2019, 70, 1600-1613.	3.6	70
39	Targeting Î²â€catenin in hepatocellular cancers induced by coexpression of mutant Î²â€catenin and Kâ€Ras in mice. Hepatology, 2017, 65, 1581-1599.	3.6	67
40	MicroRNAâ€206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met protoâ€oncogene and cyclinâ€dependent kinase 6 in mice. Hepatology, 2017, 66, 1952-1967.	3.6	65
41	Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis. Molecular Cancer Research, 2009, 7, 1937-1945.	1.5	64
42	MicroRNAâ€21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology, 2018, 67, 2414-2429.	3.6	64
43	4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and Nâ€Ras protoâ€oncogenes in mice. Hepatology, 2015, 61, 200-213.	3.6	63
44	Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. Oncotarget, 2015, 6, 10102-10115.	0.8	61
45	Both <i>de novo</i> synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. Liver International, 2017, 37, 80-89.	1.9	60
46	Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut, 2021, 70, 1746-1757.	6.1	60
47	APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut, 2019, 68, 1846-1857.	6.1	59
48	Integration of DNA Copy Number Alterations and Transcriptional Expression Analysis in Human Gastric Cancer. PLoS ONE, 2012, 7, e29824.	1.1	56
49	Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2019, 25, 403-413.	3.2	56
50	Synergistic role of sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology, 2010, 52, 506-517.	3.6	52
51	PI3K/AKT/mTORâ€dependent stabilization of oncogenic farâ€upstream element binding proteins in hepatocellular carcinoma cells. Hepatology, 2016, 63, 813-826.	3.6	52
52	Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer. Oncotarget, 2015, 6, 6977-6988.	0.8	49
53	Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. Journal of Hepatology, 2012, 57, 577-583.	1.8	45
54	Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell Cycle, 2017, 16, 499-507.	1.3	45

#	Article	IF	Citations
55	Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. Journal of Hepatology, 2021, 75, 888-899.	1.8	45
56	Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. Journal of Hepatology, 2019, 71, 742-752.	1.8	44
57	Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma. Frontiers in Oncology, 2019, 9, 1412.	1.3	44
58	Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. Experimental and Molecular Medicine, 2018, 50, e417-e417.	3.2	39
59	Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis. Cell Death and Differentiation, 2020, 27, 2330-2343.	5.0	39
60	Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade. PLoS ONE, 2017, 12, e0184068.	1.1	35
61	Axis inhibition protein 1 (Axin1) Deletionâ€“Induced Hepatocarcinogenesis Requires Intact Î²â€Catenin but Not Notch Cascade in Mice. Hepatology, 2019, 70, 2003-2017.	3.6	33
62	New tools for functional genomic analysis. Drug Discovery Today, 2009, 14, 754-760.	3.2	32
63	Nuclear factor erythroid 2â€“related factor 2 and Î²â€Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications. Hepatology, 2021, 74, 741-759.	3.6	32
64	Bmi1 Is Required for Hepatic Progenitor Cell Expansion and Liver Tumor Development. PLoS ONE, 2012, 7, e46472.	1.1	31
65	Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans. American Journal of Pathology, 2018, 188, 995-1006.	1.9	29
66	TAZ is indispensable for c-MYC-induced hepatocarcinogenesis. Journal of Hepatology, 2022, 76, 123-134.	1.8	28
67	Role of the Notch signaling in cholangiocarcinoma. Expert Opinion on Therapeutic Targets, 2017, 21, 471-483.	1.5	27
68	SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget, 2015, 6, 2222-2234.	0.8	27
69	Activated mutant forms of <scp>PIK</scp>3<scp>CA</scp> cooperate with RasV12 or câ€Met to induce liver tumour formation in mice via <scp>AKT</scp>2/<scp>mTORC</scp>1 cascade. Liver International, 2016, 36, 1176-1186.	1.9	26
70	Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development. Oncotarget, 2017, 8, 73433-73447.	0.8	26
71	TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma. American Journal of Pathology, 2019, 189, 1077-1090.	1.9	25
72	Therapeutic efficacy of FASN inhibition in preclinical models of HCC. Hepatology, 2022, 76, 951-966.	3.6	25

#	ARTICLE	IF	CITATIONS
73	Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines <i>in vitro</i> and AKT-driven hepatocarcinogenesis in mice. Oncotarget, 2017, 8, 54149-54159.	0.8	24
74	Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death and Disease, 2018, 9, 31.	2.7	23
75	Oncogene-dependent function of BRG1 in hepatocarcinogenesis. Cell Death and Disease, 2020, 11, 91.	2.7	23
76	Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yesâ€Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans. Hepatology, 2021, 74, 248-263.	3.6	22
77	TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis. Journal of Hepatology, 2021, 75, 120-131.	1.8	22
78	Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1095-1117.	2.3	21
79	Oncogenic Mutations in Armadillo Repeats 5 and 6 of Î²-Catenin Reduce Binding to APC, Increasing Signaling and Transcription of Target Genes. Gastroenterology, 2020, 158, 1029-1043.e10.	0.6	20
80	Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis. International Journal of Molecular Sciences, 2020, 21, 8467.	1.8	20
81	Molecular Mechanisms of Hepatoblastoma. Seminars in Liver Disease, 2021, 41, 028-041.	1.8	19
82	SCD1 Expression Is Dispensable for Hepatocarcinogenesis Induced by AKT and Ras Oncogenes in Mice. PLoS ONE, 2013, 8, e75104.	1.1	17
83	Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis. Oncotarget, 2017, 8, 90638-90650.	0.8	17
84	Oncogenic potential of N-terminal deletion and S45Y mutant Î²-catenin in promoting hepatocellular carcinoma development in mice. BMC Cancer, 2018, 18, 1093.	1.1	17
85	Functional role of SGK3 in PI3K/Pten driven liver tumor development. BMC Cancer, 2019, 19, 343.	1.1	17
86	Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets. Expert Review of Gastroenterology and Hepatology, 2017, 11, 349-356.	1.4	16
87	Distinct functions of transforming growth factor-Î² signaling in c-MYC driven hepatocellular carcinoma initiation and progression. Cell Death and Disease, 2021, 12, 200.	2.7	16
88	Roles of microRNA in liver cancer. Liver Research, 2018, 2, 61-72.	0.5	15
89	Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma. Cell Cycle, 2018, 17, 1496-1512.	1.3	14
90	Monocytes promote liver carcinogenesis in an oncogene-specific manner. Journal of Hepatology, 2016, 64, 881-890.	1.8	13

#	ARTICLE	IF	CITATIONS
91	mTORC2 Signaling Is Necessary for Timely Liver Regeneration after Partial Hepatectomy. American Journal of Pathology, 2020, 190, 817-829.	1.9	13
92	The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic Î²-Catenin to Induce Hepatoblastoma Development in Mice and Humans. American Journal of Pathology, 2020, 190, 1397-1413.	1.9	13
93	Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. Cell Death and Disease, 2021, 12, 920.	2.7	13
94	Î²-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma. Gastroenterology, 2022, 163, 481-494.	0.6	13
95	SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelialâ€“Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model. Cancer Research, 2019, 79, 5563-5574.	0.4	12
96	YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice. American Journal of Pathology, 2021, 191, 1651-1667.	1.9	12
97	[11C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. Molecular Imaging and Biology, 2016, 18, 360-367.	1.3	11
98	Focal adhesion kinase activation limits efficacy of Dasatinib in câ€•Myc driven hepatocellular carcinoma. Cancer Medicine, 2018, 7, 6170-6181.	1.3	11
99	Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. World Journal of Gastroenterology, 2016, 22, 2071.	1.4	11
100	MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment. Cell Death and Disease, 2019, 10, 120.	2.7	10
101	The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	10
102	On the role of notch1 and adult hepatocytes in murine intrahepatic cholangiocarcinoma development. Hepatology, 2013, 58, 1857-1859.	3.6	9
103	Role of Lipogenesis Rewiring in Hepatocellular Carcinoma. Seminars in Liver Disease, 2022, 42, 077-086.	1.8	9
104	Potential dual functional roles of the Yâ€•linked RBMY in hepatocarcinogenesis. Cancer Science, 2020, 111, 2987-2999.	1.7	9
105	Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. Cancers, 2019, 11, 930.	1.7	8
106	RASSF1A independence and early galectinâ€•1 upregulation in PIK3CAâ€•induced hepatocarcinogenesis: new therapeutic venues. Molecular Oncology, 2022, 16, 1091-1118.	2.1	8
107	Mammalian Target of Rapamycin Complex 2 Signaling Is Required for Liver Regeneration in a Cholestatic Liver Injury Murine Model. American Journal of Pathology, 2020, 190, 1414-1426.	1.9	7
108	Fascin1 empowers YAP mechanotransduction and promotes cholangiocarcinoma development. Communications Biology, 2021, 4, 763.	2.0	6

#	ARTICLE	IF	CITATIONS
109	Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opinion on Therapeutic Targets, 2021, 25, 645-658.	1.5	5
110	Selective targeting of MYC mRNA by stabilized antisense oligonucleotides. Oncogene, 2021, 40, 6527-6539.	2.6	5
111	Loss of Apc Cooperates with Activated Oncogenes to Induce Liver Tumor Formation in Mice. American Journal of Pathology, 2021, 191, 930-946.	1.9	4
112	CDK9 is dispensable for YAPâ€driven hepatoblastoma development. Pediatric Blood and Cancer, 2020, 67, e28221.	0.8	3
113	Untargeted UPLC-MS-based metabolomics analysis reveals the metabolic profile of intrahepatic cholangiocarcinoma process and the intervention effect of Osthole in mice. Pharmacological Research Modern Chinese Medicine, 2022, 3, 100096.	0.5	2
114	Reply. Hepatology, 2019, 70, 764-765.	3.6	1
115	Hydrodynamic Injection for Developing NASH Model. Methods in Molecular Biology, 2022, 2455, 31-39.	0.4	1